Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

HER2 acts an oncogenic driver in numerous cancers. Here, the authors design an anti-HER2 biparatopic and tetravalent IgG fusion with inhibitory effects in a xenograft model.

Bibliographic Details
Main Authors: Florian Kast, Martin Schwill, Jakob C. Stüber, Svende Pfundstein, Gabriela Nagy-Davidescu, Josep M. Monné Rodríguez, Frauke Seehusen, Christian P. Richter, Annemarie Honegger, Karen Patricia Hartmann, Thomas G. Weber, Felix Kroener, Patrick Ernst, Jacob Piehler, Andreas Plückthun
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-021-23948-6

Internet

https://doi.org/10.1038/s41467-021-23948-6

Similar Items